• PDB34 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS–TYPE I AND TYPE 2

    May 1, 2006, 00:00

  • PMH30 EVALUATION OF SELECTIVE SEROTONIN REPUTAKE INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION

    May 1, 2006, 00:00

  • RS2 COST-EFFECTIVENESS OFTELITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2006, 00:00

  • PMC10 THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY

    May 1, 2006, 00:00

  • PMC7 A STANDARDIZED METHODOLOGYTO MEASURE MEDICINE PRICES, AVAILABILITY, AFFORDABILITY AND PRICE COMPONENTS IN DEVELOPING AND TRANSITIONAL COUNTRIES

    May 1, 2006, 00:00

  • PDB16 BASAL BOLUS THERAPY AMONG TYPE I DIABETES PATIENTS- A COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF ANALOG-AND HUMAN-BASED INSULIN REGIMENS

    May 1, 2006, 00:00

  • PNL11 COMPARING APPLES WITH WHAT- DIFFERENT INPUTS AND ASSUMPTIONS PRODUCE DIFFERENT CONCLUSIONS IN MS ECONOMIC MODELS

    May 1, 2006, 00:00

  • PNL18 DIRECT COST BURDEN OF MIGRAINE AMONG MEMBERS OF US EMPLOYER GROUPS

    May 1, 2006, 00:00

  • POB2 COSTS OF PREMATURE DEATH ATTRIBUTED TO OBESITY IN SPAIN

    May 1, 2006, 00:00

  • PMH42 COMPLIANCE AND PERSISTENCE- A COMPARISON BETWEEN TYPICAL AND ATYPICAL ANTIPSYCHOTIC TREATMENT OF SCHIZOPHRENIA PATIENTS

    May 1, 2006, 00:00

  • PCV46 THE ALABAMA COLLABORATION FOR CARDIOVASCULAR EQUALITY PROJECT- ADAPTING AN ELECTRONIC MEDICAL RECORD ABSTRACTION TOOL FOR USE IN AN URBAN COMMUNITY HOSPITAL SETTING

    May 1, 2006, 00:00

  • PSK6 USING MEDIATION MODELS TO ASSESS THE INCREMENTAL VALUE OF QUALITY OF LIFE QUESTIONNAIRES- DLQI IN PSORIASIS

    May 1, 2006, 00:00

  • MH3 NICE'S COST-EFFECTIVENESS APPRAISAL OF CHOLINESTERASE INHIBITORS- ASKING THE RIGHT QUESTION

    May 1, 2006, 00:00

  • UR1 THE ECONOMIC IMPACT OF EPOETIN ALFA (EPO) THERAPY ON DELAYING TIME TO DIALYSIS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)

    May 1, 2006, 00:00

  • PSK4 MEDICATION-RELATED FACTORS AFFECTING HEALTH CARE OUTCOMES AND COSTS IN PATIENTS WITH PSORIASIS AND ACNE IN THE UNITED STATES

    May 1, 2006, 00:00

  • PNL16 ECONOMIC BURDEN OF PAIN DUE TO MULTIPLE SCLEROSIS IN CANADA

    May 1, 2006, 00:00

  • PCN3 AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR DELAYED NAUSEA AND VOMITING USING ELECTRONIC MEDICAL RECORDS

    May 1, 2006, 00:00

  • PHP8 BRITISH COLUMBIAN PHYSICIANS' OPINIONS REGARDING REFERENCE DRUG AND GENERIC SUBSTITUTION PROGRAMS

    May 1, 2006, 00:00

  • PNL1 CLINICAL EFFECTIVENESS AND HEALTH OUTCOMES OF DISEASE MODIFYING TREATMENT (DMT) THAT DELAYS DISABILITY PROGRESSION IN RELAPSING/REMITTING-ONSET MULTIPLE SCLEROSIS- NOVA SCOTIA “REAL WORLD” EVIDENCE

    May 1, 2006, 00:00

  • PEY7 VARIATIONS IN PHYSICIAN PRESCRIBING OF TOPICAL MEDICATIONS FOR GLAUCOMA IN US OUTPATIENT SETTINGS

    May 1, 2006, 00:00

  • PMH18 ANALYZING PATTERNS OF ANTIDEPRESSANT USE AND THE COST CONSEQUENCES OF PRODUCT SWITCHING

    May 1, 2006, 00:00

  • PMH26 REVIEW ON HEALTH OUTCOMES ASSOCIATED WITH DEPOT ANTIPSYCHOTIC AGENTS AND LONG-ACTING RISPERIDONE INJECTABLE (LARI) FOR TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PIN11 THE IMPACT OF MECHANICAL VENTILATION ON OUTCOMES AND COSTS IN NOSOCOMIAL PNEUMONIA

    May 1, 2006, 00:00

  • PCV24 AFRICAN AMERICANS' RESPONSES TO DIRECT-TO-CONSUMER ADVERTISING (DTCA) OF LIPITOR®

    May 1, 2006, 00:00

  • PMC26 CONVERTING SF-36 INTO EQ-5D- DESIGNED TO SUCCEED OR CALCULATED TO FAIL?

    May 1, 2006, 00:00

  • PCN2 EFFECTIVENESS OF A COMMUNITY—BASED PROSTATE CANCER EDUCATION KIOSK FOR AFRICAN AMERICAN MEN- ANALYSES OF COST, SATISFACTION, QUALITY, KNOWLEDGE, AND INTENTION VARIABLES

    May 1, 2006, 00:00

  • POS12 PATIENT ADHERENCE WITH BISPHOSPHONATES AT 6 MONTHS- A RETROSPECTIVE COHORT STUDY

    May 1, 2006, 00:00

  • PMC13 APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY

    May 1, 2006, 00:00

  • PIH14 RECALL PERIODS FOR SATISFACTION WITH SEXUAL INTERCOURSE- TWO APPROACHES FOR ASSESSING OUTCOMES

    May 1, 2006, 00:00

  • PCN5 QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH BREAST CANCERAND ITS ECONOMIC CONSEQUENCES IN MEXICO

    May 1, 2006, 00:00

  • PCN23 THE EFFECT OF ORGANIZED MAMMOGRAPHY SCREENING ON THE NUMBER OF BREAST SURGERIES

    May 1, 2006, 00:00

  • PEY8 ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA

    May 1, 2006, 00:00

  • PAS11 PROPENSITY SCORE MATCHING WITH MORE THAN TWO CATEGORIES

    May 1, 2006, 00:00

  • PCV2 RETROSPECTIVE STUDY OF PATIENTS WITH CABG REOPERATION AND OUTCOMES

    May 1, 2006, 00:00

  • PG11 HEPATITIS B IMMUNISATION FOR NEWBORNS OF HEPATITIS B SURFACE ANTIGEN-POSTITIVE MOTHERS- A COCHRANE HEPATO-BILIARY GROUP SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2006, 00:00

  • PUK12 QUALITY OF LIFE IN YOUNG MEN AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER- RESULTS FROM THE CAPSURE REGISTRY

    May 1, 2006, 00:00

  • PNL19 ECONOMIC BURDEN OF RESTLESS LEGS SYNDROME INA PRIVATELY-INSURED POPULATION

    May 1, 2006, 00:00

  • POS13 COMPLIANCE, DISCONTINUATION, AND SWITCHING OF OSTEOPOROSIS TREATMENT IN LOUISIANA MEDICAID POST-MENOPAUSAL WOMEN

    May 1, 2006, 00:00

  • PAS5 RELATIONSHIP OF PATIENT CHARACTERISTICS AND RESOURCE USE IN SEVERE ASTHMA

    May 1, 2006, 00:00

  • PMC20 A BAYESIAN APPROACH TO PREDICT EFFECTIVENESS OF NEWLY INTRODUCED DRUGS IN DAILY PRACTICE BASED ON THE RELATION BETWEEN EFFICACY AND EFFECTIVENESS OF COMPETING INTERVENTIONS

    May 1, 2006, 00:00

  • PCN35 DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC, NEUROENDOCRINE TUMOR QUESTIONNAIRE (QOL-NET). TO MEASURE PATIENTS' PERCEPTION OF THE EFFECTS OF DISEASE ON THEIR QUALITY OF LIFE (QOL)

    May 1, 2006, 00:00

  • PR8 THE IMPACT OF ABNORMAL UTERINE BLEEDING ON HEALTH-RELATED QUALITY OF LIFE- A META-ANALYSIS

    May 1, 2006, 00:00

  • PNL22 ESTIMATING THE COST OF NURSING HOME CARE FOR PATIENTS WITH PARKINSON'S DISEASE USING RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • POS2 THE EFFECT OF RISK FACTORS ON MORTALITY AFTER PRIMARYTREATMENT OF FEMORAL NECK FRACTURE AT DIFFERENT TIME PERIODS IN HUNGARY

    May 1, 2006, 00:00

  • PCN12 COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL) RECEIVING CHOP

    May 1, 2006, 00:00

  • PGI19 OBJECTIVE MEASUREMENT OF PRODUCTIVITY WHILE AT WORK IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE

    May 1, 2006, 00:00

  • PCV43 AN EMPIRICAL EVALUATION OF THE EXPECTED VALUE OF PERFECT INFORMATION

    May 1, 2006, 00:00

  • PER1 ECONOMIC EVALUATION OF STRATEGIES FOR SCREENING NEWBORNS FOR BILATERAL HEARING IMPAIRMENT IN FRANCE

    May 1, 2006, 00:00

  • PNL10 COST-EFFECTIVENESS OF MS DISEASE MODIFYING AGENTS- A MARKOV ANDVALUE OF INFORMATION ANALYSIS

    May 1, 2006, 00:00

  • PCN18 CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY

    May 1, 2006, 00:00

  • HE4 RACIAL/ETHNIC DISPARITIES IN LENGTH OF STAY AND COST OF INPATIENT CARE FOR INTRACEREBRAL HEMORRHAGE- EVIDENCE FROM THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE

    May 1, 2006, 00:00

  • PHP2 MEMBERS INITIAL EXPERIENCE WITH A CONSUMER-DRIVEN PHARMACY BENEFIT PLAN DESIGN

    May 1, 2006, 00:00

  • MH4 MEDICAL COSTS AND HOSPTALIZATION OF ADULTS DIAGNOSED WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER WHO RECEIVED ALTERNATIVE THERAPIES

    May 1, 2006, 00:00

  • PGI20 SUBJECTIVE REASONS FOR NONCOMPLIANCE WITH MEDICATION REGIMEN IN INFLAMMATORY BOWEL DISEASE PATIENTS

    May 1, 2006, 00:00

  • PNL9 COST-EFFECTIVENESS OFTOPIRAMATE FOR MIGRAINE PREVENTION- A MANAGED CARE PERSPECTIVE

    May 1, 2006, 00:00

  • PCV57 DOES 90-DAY PRESCRIPTION SUPPLY AT RETAIL IMPROVE COMPLIANCE IN A MANAGED CARE SETTING]

    May 1, 2006, 00:00

  • PHP20 ISPOR CONTRIBUTED RESEARCH 1998-2005- EVALUATION OF TRENDS QUALITY INDICATORS

    May 1, 2006, 00:00

  • PG17 COST-EFFECTIVENESS (C-E) OFTEGASEROD VS. PLACEBO FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

    May 1, 2006, 00:00

  • CN4 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING

    May 1, 2006, 00:00

  • PHM4 COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA

    May 1, 2006, 00:00

  • PUK14 WORK PRODUCTIVITY IN PATIENTS WITH OVERACTIVE BLADDER- RESULTS FROM THE MATRIX STUDY

    May 1, 2006, 00:00

  • MH2 USE PATTERNS AND OUTCOMES ASSOCIATED WITH TYPICAL DEPOT ANTIPSYCHOTIC AGENTS IN THE SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP)—AUSTRALIA

    May 1, 2006, 00:00

  • PCN10 COST-EFFECTIVENESS OF GEMCITABINE-PACLITAXEL COMBINATION IN THE TREATMENT OF ADVANCED BREAST CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY

    May 1, 2006, 00:00

  • PMC5 ARE NON-INFERIORITY TRIALS SUITABLE FOR ECONOMIC EVALUATION? ESTIMATION IS STILL MORE IMPORTANT THAN HYPOTHESIS TESTING

    May 1, 2006, 00:00

  • PAR11 WITHDRAWAL OF COX-2 INHIBITOR ROFECOXIBAND VALDECOXIB- IMPACT ON NSAIDAND PPI PRESCRIPTIONS AND EXPENDITURES

    May 1, 2006, 00:00

  • PCN33 MAPPING FACT-PAND EORTC QLQ-C30TOTHE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS

    May 1, 2006, 00:00

  • PCV10 LOSS OF COMBINED OPTIMAL LIPID VALUE ACHIEVEMENT AND THE RISK OF CARDIOVASCULAR EVENTS

    May 1, 2006, 00:00

  • PIH15 BARRIERS TO COMMUNICATION ABOUT ERECTILE DYSFUNCTION IN PATIENTS TAKING ANTIHYPERTENSIVE MEDICATIONS

    May 1, 2006, 00:00

  • PMC22 ALLOCATION OF PRESCRIPTION DATA BY INDICATION- A METHODOLOGY INTEGRATING COMPLEMENTARY PATIENT-LEVEL INFORMATION SOURCES

    May 1, 2006, 00:00

  • POS5 THE COST-EFFECTIVENESS OF IBANDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN THE US

    May 1, 2006, 00:00

  • PCV62 UNDERSTANDING PATIENT BELIEFS TO DESIGN MEDICATION ADHERENCE MESSAGING

    May 1, 2006, 00:00

  • PNL14 COST-EFFECTIVENESS OF PREGABALIN AS ADJUNCT TO STANDARD THERAPY IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY

    May 1, 2006, 00:00

  • PAR3 RETROSPECTIVE STUDY ON THE ADVERSE EVENTS OF ARTHRITIC PATIENTS TREATED WITH VIOXX AND OTHER ARTHRITIS PAINKILLERS

    May 1, 2006, 00:00

  • PCV34 DEVELOPING HOSPICE DRUG FORMULARY USING MULTI-ATTRIBUTE UTILITYTHEORY (MAUT) METHODOLOGY

    May 1, 2006, 00:00

  • Abstracts Index

    May 1, 2006, 00:00

  • PNL4 COMPARING THE RELATIVE COST-EFFECTIVENESS OF ORAL PROPHYLACTIC MEDICATION VS. BOTULINUM TOXIN TYPE A (BOTOX®) IN THE MANAGEMENT OF MIGRAINE HEADACHE- A MODEL EVALUATING THE CLINICAL AND ECONOMIC IMPACT OF CURRENT TREATMENT OPTIONS

    May 1, 2006, 00:00

  • CS1 THE ECONOMIC AND HEALTH CONSEQUENCES IN SWEDEN OF MANAGING BRADYCARDIA WITH ADAPTA® COMPARED TO A STANDARD DUAL CHAMBER PACEMAKER

    May 1, 2006, 00:00

  • PEY1 PREVALENCE OF INTRAOCULAR HYPERTENSION AND GLAUCOMA IN AN UNSELECTED FRENCH POPULATION

    May 1, 2006, 00:00

  • PNL21 PATTERNS OF TOPIRAMATE UTILIZATION AMONG MEDICAID PATIENTS- DIAGNOSIS, COMORBIDITIES AND REAL-WORLD DOSING

    May 1, 2006, 00:00

  • PCV3 THE IMPACT OF MYOCARDIAL PERFUSION IMAGING FOR DETECTION OF CORONARY ARTERY DISEASE ON THE HEALTH OUTCOMES OF ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PCN20 COSTS OF THE DIFFERENT TREATMENTS FOR PATIENTS WITH BREAST CANCER IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)

    May 1, 2006, 00:00

  • PIN19 A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOMES IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL

    May 1, 2006, 00:00

  • PNL13 WINNERS AND LOSERS- PATTERNS IN ECONOMIC EVALUATIONS OF ANTI-EPILEPTIC DRUGS

    May 1, 2006, 00:00

  • PCV19 ONE-YEAR COSTS FORACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT REVASCULARIZATION DURING THE INITIAL HOSPITALIZATION

    May 1, 2006, 00:00

  • PCV35 SINGLE SOURCE COST ESTIMATES FOR EVENTS ACROSS VARIOUS CONDITIONS REQUIRING THROMBOEMBOLIC PROPHYLAXIS AND TREATMENT

    May 1, 2006, 00:00

  • PIN1 HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS INFECTION-A META-ANALYSIS

    May 1, 2006, 00:00

  • PR5 VALIDATION OF THE HYPERPIGMENTATION TREATMENT SATISFACTION QUESTIONNAIRE (HPTSQ)

    May 1, 2006, 00:00

  • PCN32 MODELING AND ESTIMATING PREFERENCES OVER TREATMENTS FOR BREAST CANCER- APPLIED CONJOINT ANALYSIS WITH PHYSICIANS IN EUROPE AND UNITED STATES

    May 1, 2006, 00:00

  • PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE

    May 1, 2006, 00:00

  • PCV58 ADHERENCE TO EVIDENCE-BASED STATIN GUIDELINES REDUCES RISK FORACUTE MYOCARDIAL INFARCTION WITH AT LEAST 50%.

    May 1, 2006, 00:00

  • PHP28 THE EFFECT OF HIGH-RISK MEDICATIONS ON VISIT TIME WITH PHYSICIANS- RESULTS FROM THE NAMCS SURVEY

    May 1, 2006, 00:00

  • CE1 PHARMACOECONOMIC EVALUATION OF SINGLE DOSE AZITHROMYCIN EXTENDED RELEASE (AZ-ER) FORTHE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    May 1, 2006, 00:00

  • PMH48 MEASUREMENT OF UTILITY LOSSES IN DEPRESSION

    May 1, 2006, 00:00

  • PCV40 VARIATION OF COST-TO-CHARGE RATIO FOR CABG PATIENT BY HOSPITAL TYPE OVERTIME

    May 1, 2006, 00:00

  • Where's the Value in Health Care?

    May 1, 2006, 00:00

  • PMH44 ECONOMIC CONSEQUENCES OF PATIENTS NOT ADHERING TO MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • UR2 ECONOMIC BURDEN OF UNTREATED ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) PATIENTS- AN EMPLOYER'S PERSPECTIVE

    May 1, 2006, 00:00

  • PIN5 COST EFFECTIVENESS OF ADDING 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE TO A CHILDHOOD VACCINATION—IMPACT OF HERD IMMUNITY

    May 1, 2006, 00:00

  • PHP17 IMPACT OF CO-PAY DIFFERENTIAL ON GENERIC PRESCRIPTIONS FILLED THROUGH 90-DAY RETAIL CHANNEL

    May 1, 2006, 00:00

  • PDB5 NEGATIVE PRESSURE WOUND THERAPY ASSOCIATION WITH REDUCED OCCURRENCE OF DIABETIC FOOT ULCER AMPUTATIONS-A RETROSPECTIVE STUDY OF PAYOR CLAIMS DATA

    May 1, 2006, 00:00

  • PMH32 ANTIPSYCHOTIC THERAPY IN PATIENTS WITH BIPOLAR DISORDER- EFFECTS ON TOTAL AND MENTAL HEALTH CARE COSTS

    May 1, 2006, 00:00

  • PNL29 A REVIEW OF THE VALIDITY AND RELIABILITY OF THE PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-39)

    May 1, 2006, 00:00

  • PCV25 USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY HYPERTENSIVE PATIENTS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PDB13 COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN ADDING FENOFIBRATE TO TREATMENT WITH A STATIN

    May 1, 2006, 00:00

  • PIN20 COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE

    May 1, 2006, 00:00

  • PIN15 THE EXPECTED ECONOMIC BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI)

    May 1, 2006, 00:00

  • PNL24 THE ESTIMATION POWER OF ALTERNATIVE COMORBIDITY INDEXES

    May 1, 2006, 00:00

  • PIN8 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA IN ARGENTINA

    May 1, 2006, 00:00

  • PUK11 ESTIMATING A PREFERENCE-BASED SINGLE INDEX FROM THE OVERACTIVE BLADDER QUESTIONNAIRE

    May 1, 2006, 00:00

  • PG18 A COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR ESOPHAGEAL VARICES- HOW GOOD DOES A CLINICAL DECISION AID HAVE TO BE?

    May 1, 2006, 00:00

  • PSK2 PHYSICIAN AND PATIENT RELATED DETERMINANTS OF PRESCRIBING TOPICAL CALCINEURIN INHIBITORS FOR PATIENTS WITH ATOPIC DERMATITIS- ANALYSIS OF U.S. NATIONAL OUTPATIENTVISIT DATA

    May 1, 2006, 00:00

  • PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA)

    May 1, 2006, 00:00

  • PCV18 ECONOMIC EVALUATION OF ORAL THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION

    May 1, 2006, 00:00

  • DB2 SELF REPORTED PREDICTORS OF DEPRESSIVE SYMPTOMATOLOGY IN AN ELDERLY POPULATION WITH TYPE 2 DIABETES MELLITUS

    May 1, 2006, 00:00

  • PDB15 COST-UTILITY ANALYSIS OF ANALOG BASAL BOLUS THERAPY AMONG INSULIN-DEPENDENT DIABETES PATIENTS

    May 1, 2006, 00:00

  • POB7 OBESITY AND QUALITY OF LIFE IN THE UNITED STATES- 2000-2002

    May 1, 2006, 00:00

  • PCV53 STATIN NONCOMPLIANCE AFTER CHD HOSPITALIZATION AND SUBSEQUENT HOSPITALIZATION AMONG NEW STATIN USERS

    May 1, 2006, 00:00

  • POS6 COST OF FALLS IN LONG-TERM CARE FACILITIES (LTCFS)

    May 1, 2006, 00:00

  • HE1 ECONOMIC EVALUATION OF A 90-DAY RETAIL PRESCRIPTION DRUG PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING

    May 1, 2006, 00:00

  • PIH2 A COST EFFECTIVENESS STUDY OF CARBETOCINE COMPARED TO OXYTOCIN FORTHE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS

    May 1, 2006, 00:00

  • ID1 “GATEKEEPERS AND SENTINELS”- IMPLICATIONS FOR DRUG UTILIZATION POLICY IN THE COMMUNITY SETTING

    May 1, 2006, 00:00

  • PHP24 ELECTRONIC INTERFACES FOR SHARING PATIENT DATA- ESTIMATING RETURN ON INVESTMENT IN HOSPICE

    May 1, 2006, 00:00

  • PEY5 ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY (VISUDYNE®) COMPARED TO USUAL CARE IN THE TREATMENT OF AGE RELATED MACULAR DEGENERATION (ARMD) IN USA

    May 1, 2006, 00:00

  • PHM3 ECONOMIC ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE HOME TREATMENT OF MINOR-TO-MODERATE BLEEDS IN HEMOPHILIA PATIENTS WITH INHIBITORS- A U.S. COST-OF-BLEED MODEL

    May 1, 2006, 00:00

  • RS1 TRENDS IN MEDICATION PRESCRIBING FOR CHILDREN WITH SLEEP DISORDERS IN US OUTPATIENT SETTINGS

    May 1, 2006, 00:00

  • PAS10 A SYSTEMATIC OVERVIEW OF THE MEASUREMENT PROPERTIES OF THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN ASTHMA

    May 1, 2006, 00:00

  • PAR17 A COMPARISON OF HEALTH RELATED QUALITY OF LIFE (HRQOL) OF PERSONS WITH AND WITHOUT ARTHRITIS OR CHRONIC JOINT SYMPTOMS (CJS)

    May 1, 2006, 00:00

  • PDB12 A MARKOV MODEL TO ASSESS THE COST-EFFECTIVENESS OF A CONTINUOUS GLUCOSE MONITORING SYSTEM WITH TRENDING AND RATE INFORMATION WHEN USED TO PREDICT AND PREVENT HYPO-AND HYPERGLYCEMIA IN PATIENTS WITH TYPE I DIABETES

    May 1, 2006, 00:00

  • PDB25 MARGINAL STRUCTURAL MODELS—AN EXPLANATION AND ILLUSTRATION

    May 1, 2006, 00:00

  • CE3 SHORT-TERM COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE

    May 1, 2006, 00:00

  • PGI17 TRENDS IN AMBULATORY CARE UTILIZATION FOR CONSTIPATION AND IRRITABLE BOWEL SYNDROME- 1993-2003

    May 1, 2006, 00:00

  • AC1 USING TABLET PCS FOR SMOKING HAZARDS EDUCATION IN A METHADONE CLINIC

    May 1, 2006, 00:00

  • PMH20 COST OF TREATMENT OF HYPERKINETIC DISORDER IN GERMANY

    May 1, 2006, 00:00

  • PCNI5 THE ANNUAL HEALTH INSURANCE COST OF COLORECTAL CANCER TREATMENT IN HUNGARY-A COST OF ILLNESS STUDY

    May 1, 2006, 00:00

  • PHM5 PILOT STUDYTO ESTABLISH PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES USED TO TREAT HAEMOPHILIC PATIENTS WITH INHIBITORS

    May 1, 2006, 00:00

  • PPN4 PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO PATIENT CONTROLLED ANALGESIA

    May 1, 2006, 00:00

  • CV3 SWITCHING, AUGMENTATION AND TITRATION OF LIPID LOWERING AGENTS OF MEDICARE/MEDICAID DUAL ELIGIBLE PATIENTS BY ETHNICITY

    May 1, 2006, 00:00

  • ID3 TRENDS IN HIVTREATMENT EXPERIENCE AND OUTCOMES AS OBSERVED IN A SAMPLE OF PATIENTS FROM A US CLINICAL DATABASE

    May 1, 2006, 00:00

  • PRS8 THE COST-EFFECTIVENESS OF PALIVIZUMAB IN AUSTRIA

    May 1, 2006, 00:00

  • PNL31 HEALTHCARE UTILIZATION AND PATIENT SATISFACTION WITH TRIPTAN TREATMENT IN MIGRAINEURS

    May 1, 2006, 00:00

  • PAR9 A PHARMACOECONOMIC EVALUATION FORTHE TREATMENT OF ARTICULAR PAIN IN PATIENTS WITH OSTEOARTHRITIS IN MEXICO

    May 1, 2006, 00:00

  • PSK1 PATTERNS FOR PHOTOTHERAPY USE IN TREATMENT OF MODERATE-TO-SEVERE PSORIASIS

    May 1, 2006, 00:00

  • PAL1 DIAGNOSTIC TESTING FOR ALLERGIC RHINITIS- EVALUATING TEST DECISION AND TEST VALUE

    May 1, 2006, 00:00

  • POB4 USE OF GROWTH CURVE ANALYSES FOR DISCRETE EVENT SIMULATION- A CASE STUDY OF POOLED CLINICAL TRIALS OF THE EFFECTS OF RIMONABANT ON CARDIOMETABOLIC RISK FACTORS IN OBESE PATIENTS

    May 1, 2006, 00:00

  • PCN29 GAPS IN THE ECONOMIC EVALUATION OF PROSTATE CANCER

    May 1, 2006, 00:00

  • CE2 THE COST-EFFECTIVENESS OF ZEMPLAR IN THE NETHERLANDS

    May 1, 2006, 00:00

  • PER2 OUTCOMES ASSOCIATED WITH AN OTITIS PARENT QUESTIONNAIRE IN PEDIATRIC PATIENTS WITH ACUTE OTITIS MEDIA FOLLOWING ADMINISTRATION OF CEFDINIR ORAL SUSPENSION OR HIGH DOSE AMOXICILLIN/CLAVULANATE ORAL SUSPENSION

    May 1, 2006, 00:00

  • The Return on Investment in Health Care- From 1980 to 2000

    May 1, 2006, 00:00

  • PAR15 PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS

    May 1, 2006, 00:00

  • PCV33 PRESCRIPTION DRUG INSURANCE STATUS AND UTILIZATION OF ANTI-HYPERLIPIDEMICS- RESULTS FROM THE 2000 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2006, 00:00

  • Disclosure Information

    May 1, 2006, 00:00

  • PCN13 COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY

    May 1, 2006, 00:00

  • PMH7 ANNUAL COSTS ASSOCIATED WITH PATTERNS OF ANTIDEPRESSANT TREATMENT RESPONSE AMONG EMPLOYEES

    May 1, 2006, 00:00

  • PHP10 CHARACTERISTICS OF SENIORS WITH HIGH ANNUAL PRESCRIPTION DRUG EXPENDITURES- FINDINGS FROM THE 2002 AND 2003 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2006, 00:00

  • PSM1 POTENTIAL BENEFITS OF SMOKING CESSATION TREATMENT COVERAGE AT THE WORKPLACE

    May 1, 2006, 00:00

  • PUK2 ASSOCIATION BETWEEN IN-HOSPITAL FALLS, COMORBIDITIES, AND DRUG USE IN ADULT CHRONIC KIDNEY DISEASE PATIENTS- A CASE-CONTROL STUDY

    May 1, 2006, 00:00

  • PMH39 COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS

    May 1, 2006, 00:00

  • PCN39 A SYSTEMATIC REVIEW OF THE UCLA PROSTATE CANCER INDEX'S MEASUREMENT PROPERTIES

    May 1, 2006, 00:00

  • PCV59 LONG-TERM CARDIOVASCULAR OUTCOMES OF COMPLIANCE AND PERSISTENCE WITH HYPERTENSION THERAPY

    May 1, 2006, 00:00

  • PCV50 STATIN THERAPY PERSISTENCE IN A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PDB7 COST IMPACT ASSOCIATED WITH INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS

    May 1, 2006, 00:00

  • PCN45 EFFECT OF AGE ON PREFERENCES FOR HEALTH OUTCOMES IN PROSTATE CANCER

    May 1, 2006, 00:00

  • PCN26 INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD- PARENT VERSUS CLINICIAN ASSESSMENT

    May 1, 2006, 00:00

  • PHP15 THE CORRELATION OF SATISFACTION OF MEDICARE BENEFICIARIES WITH ACCESS AND QUALITY OF CARE

    May 1, 2006, 00:00

  • PMH11 A COST-EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CHRONIC SCHIZOPHRENIA IN MEXICO

    May 1, 2006, 00:00

  • PIN10 COST EFFECTIVENESS OFTIPRANAVIR IN TREATMENT-EXPERIENCED HIV PATIENTS IN THE USA

    May 1, 2006, 00:00

  • PIH11 DEVELOPMENT AND VALIDATION OF THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY

    May 1, 2006, 00:00

  • Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia- Results from a Randomized, Open-Label, 1-Year Trial

    Mar 1, 2006, 00:00

  • Validation of Electronic Data Capture of the Irritable Bowel Syndrome—Quality of Life Measure, the Work Productivity and Activity Impairment Questionnaire for Irritable Bowel Syndrome and the EuroQol

    Mar 1, 2006, 00:00

  • The Instrumental Variable Method to Study Self-Selection Mechanism- A Case of Influenza Vaccination

    Mar 1, 2006, 00:00

  • Incorporating Direct and Indirect Evidence Using Bayesian Methods- An Applied Case Study in Ovarian Cancer

    Mar 1, 2006, 00:00

  • Psychometric Evaluation of a New Questionnaire Measuring Treatment Satisfaction in Hypothyroidism- The ThyTSQ

    Mar 1, 2006, 00:00

  • Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery

    Mar 1, 2006, 00:00

  • Performance of the EQ-5D in Patients with Irritable Bowel Syndrome

    Mar 1, 2006, 00:00

  • Determinants of Health Economic Decisions in Actual Practi The Role of Behavioral Economics

    Mar 1, 2006, 00:00

  • A Primer on Dynamic Optimization and Optimal Control in Pharmacoeconomics

    Mar 1, 2006, 00:00

  • Developing Better Economic Models of Osteoporosis- Considerations for the Calculation of the Relative Risk of Fracture

    Jan 1, 2006, 00:00

  • Measurement of HRQL Using EQ-5D in Patients with Type 2 Diabetes Mellitus in Japan

    Jan 1, 2006, 00:00

  • Systematic Screening for Chlamydia trachomatis- Estimating Cost-Effectiveness Using Dynamic Modeling and Dutch Data

    Jan 1, 2006, 00:00

  • Pramipexole versus Levodopa in Patients with Early Parkinson's Disease- Effect on Generic and Disease-Specific Quality of Life

    Jan 1, 2006, 00:00

  • The New Injury Severity Score- Better Prediction of Functional Recovery after Musculoskeletal Injury

    Jan 1, 2006, 00:00

  • Discrepancies between Patient-Reported Outcomes and Clinician-Reported Outcomes in Chronic Venous Disease, Irritable Bowel Syndrome, and Peripheral Arterial Occlusive Disease

    Jan 1, 2006, 00:00

  • A Comparison of Depressive Symptoms in Stroke and Primary Care- Applying Rasch Models to Evaluate the Center for Epidemiologic Studies-Depression Scale

    Jan 1, 2006, 00:00

  • Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany

    Jan 1, 2006, 00:00

  • PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

    Nov 1, 2005, 00:00

  • PIH2 THE COST OF PREMATURITY- TWO NEONATAL INTENSIVE CARE UNITS (NICUS) FROM UNIVERSITY HOSPITALS OF ATHENS

    Nov 1, 2005, 00:00

  • PIN22 COST-UTILITY ANALYSIS OF A HYPOTHETICAL VACCINATION PROGRAM AMONG THE CURRENTLY TARGETED POPULATION IN THE NETHERLANDS IN CASE OF AN INFLUENZA PANDEMIC

    Nov 1, 2005, 00:00

  • PCV33 A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PHP7 MANAGING ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS- EMERGENCY DEPARTMENT AND INPATIENT HOSPITAL RESOURCE USE AND COSTS

    Nov 1, 2005, 00:00

  • PIN12 ASSESSEMENT OF THE EFFECT OF DROTRECOGIN ALPHA (ACTIVATED)TREATMENT OF SEVERE SEPSIS ON BLEEDING EVENTS WITH COUNT MODELS

    Nov 1, 2005, 00:00

  • CN2 COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK

    Nov 1, 2005, 00:00

  • PRS17 QUALITY OF LIFE IN COPD- HOW CAN WE MEASURE IT?

    Nov 1, 2005, 00:00

  • PAL2 ATTRIBUTES FOR PREFERENCE OF NEW FAST DISSOLVING TABLET (FDT) FORMULATION OF EBASTINE IN PATIENTS WITH ALLERGY

    Nov 1, 2005, 00:00

  • PMH32 NEUROLEPTIC TREATMENT OF SCHIZOPHRENIA IN AMBULATORY CARE IN GERMANY

    Nov 1, 2005, 00:00

  • PCN52 ASSESSING QOL IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • PCN39 APPLICATION OF AN ALGORITHM FOR DEFINING RETROSPECTIVE COHORTS OF COLORECTAL CANCER (CRC) PATIENTS TREATED WITH DIFFERENT FIRST-LINE CHEMOTHERAPY REGIMENS +/− BEVACIZUMABTO ADMINISTRATIVE CLAIMS DATA

    Nov 1, 2005, 00:00

  • PMH49 QUALITY OF LIFE IN MAJOR DEPRESSION- RESULTS OF THE MC4 TRIAL

    Nov 1, 2005, 00:00

  • PCV75 COST-EFFECTIVENESS OF EPTIFIBATIDE IN NSTEMI PATIENTS IN POLAND

    Nov 1, 2005, 00:00

  • PNL5 A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD'S EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY

    Nov 1, 2005, 00:00

  • PGI21 BURDEN OF ILLNESS OF IBS PATIENTS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PCN21 TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES IN GERMANY

    Nov 1, 2005, 00:00

  • PCV46 COST-ANALYSIS OF HYPERCHOLESTEROLEMIATREATMENTS WITHIN THE SLOVAK PHARMACEUTICAL MARKET

    Nov 1, 2005, 00:00

  • PIH11 WORKAND HEALTH CONDITIONS DURING PREGNANCY IN WOMEN OF THE MEXICAN SOCIAL SECURITY INSTITUTE

    Nov 1, 2005, 00:00

  • POB10 VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES

    Nov 1, 2005, 00:00

  • PDB37 COSTS OF STAYS OF CARDIOVASCULAR EVENTS OF DIABETIC PATIENTS IN THE FRENCH HOSPITALS

    Nov 1, 2005, 00:00

  • PHP29 REIMBURSEMENT OF HIGH-PRICED NEW EMERGING MEDICAL TECHNOLOGIES IN A DRG-BASED HOSPITAL CARE SYSTEM

    Nov 1, 2005, 00:00

  • PUK6 ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS WITH OVERACTIVE BLADDER

    Nov 1, 2005, 00:00

  • PCV22 CASE-BASED-COSTING VS. MARKOV-MODELLING—A COMPARISON OF COST-EFFECTIVENESS-ANALYSES FOR CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE

    Nov 1, 2005, 00:00

  • POB3 THE ECONOMIC BURDEN OF ADULT OBESITY, WITH SPECIAL REFERENCE TO DRUG CONSUMPTION- ESTIMATES FROM THE KORA STUDY REGION

    Nov 1, 2005, 00:00

  • PIN30 INCIDENCE, PREVALENCE AND COSTS OF TREATING GENITAL WARTS IN THE PRE-HPVVACCINE ERA IN GERMANY, 2005

    Nov 1, 2005, 00:00

  • PSN8 EXAMINATION OF ADHERENCE TO PHARMACOTHERAPY TREATMENT GUIDELINES IN PATIENTS WITH PSORIASIS IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PMC3 INTERNATIONAL VARIATION IN CLINICAL INJURY INCIDENCE- REAL OR ARTIFICIAL DIFFERENCES?

    Nov 1, 2005, 00:00

  • PDB44 USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR PREVENTION IN PRIMARY CARE PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2005, 00:00

  • PCV43 IMPACT OF NEW EUROPEAN (ESC 2003) GUIDELINES ON TREATMENT OF HYPERCHOLESTEROLEMIA IN DAILY PRACTICE

    Nov 1, 2005, 00:00

  • PFM4 DIAGNOSIS OF FIBROMYALGIA AND HEALTH CARE RESOURCE USE IN PRIMARY CARE IN THE UK

    Nov 1, 2005, 00:00

  • IC4 ECONOMIC ANALYSIS OF THE STRATEGY STUDY- TIROFIBAN AND DRUG ELUTING STENTS VERSUS ABCIXIMAB AND BARE METAL STENTS

    Nov 1, 2005, 00:00

  • PGI8 ECONOMIC EVALUATION OF ADACOLUMN® APHERESIS FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE (CD)/ULCERATIVE COLITIS (UC)

    Nov 1, 2005, 00:00

  • PMH6 TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- ARE U.S. COST-EFFECTIVENESS FINDINGS BASED UPON THE MTA STUDY RELEVANTTO MENTAL HEALTH CARE POLICY MAKERS IN GERMANY?

    Nov 1, 2005, 00:00

  • PCV4 HOW MUCH IS THE ACUTE CORONARY SYNDROMES IN-HOSPITAL THERAPY- A PILOT STUDY ON THERAPY

    Nov 1, 2005, 00:00

  • PMC15 DIRECT AND INDIRECT COSTS AND EFFECTS IN COST-EFFECTIVENESS ANALYSIS OF PREVENTION- A DYNAMIC MODELLING ANALYSIS

    Nov 1, 2005, 00:00

  • Using a Treatment Satisfaction Measure in an Early Trial to Inform the Evaluation of a New Treatment for Benign Prostatic Hyperplasia

    Nov 1, 2005, 00:00

  • PDB47 TYPE-2 DIABETES AND GLYCEMIC CONTROL IN GERMANY

    Nov 1, 2005, 00:00

  • PMH47 COST OF AFFECTIVE DISORDERS IN EUROPE

    Nov 1, 2005, 00:00

  • PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481)

    Nov 1, 2005, 00:00

  • PSN15 QUALITY OF LIFE IMPROVEMENT AS MEASURED BY EQ-5D IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

    Nov 1, 2005, 00:00

  • PIN11 A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOME IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL

    Nov 1, 2005, 00:00

  • PMH46 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY

    Nov 1, 2005, 00:00

  • PHP10 THE IMPACT OF MEDICARE MANAGED CARE ON USE OF VA PHARMACY SERVICES

    Nov 1, 2005, 00:00

  • PRS3 COST ANALYSIS OF FOURTREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE- AN APPLICATION ON NON-PARAMETRIC BOOTSTRAP

    Nov 1, 2005, 00:00

  • PDB53 INTERNAL VALIDATION OF THE ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG-TERM EFFECTS (EAGLE) DIABETES MODEL

    Nov 1, 2005, 00:00

  • PMC4 THE CONTRIBUTION OF PREVENTION AND MEDICAL CARE TO POPULATION HEALTH

    Nov 1, 2005, 00:00

  • PCV40 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CORONARY HEART DISEASE- A STUDY USING EQ-5D QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PMH45 COST EFFECTIVENESS OF DULOXETINE COMPARED WITH VENLAFAXINE-XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

    Nov 1, 2005, 00:00

  • PDB39 EVALUATION OF THE COST-UTILITY OF INSULIN DETEMIR COMPARED TO INSULIN GLARGINE, BOTH IN COMBINATION WITH INSULIN ASPART INTYPE-I DIABETES IN GERMANY AND AUSTRIA

    Nov 1, 2005, 00:00

  • PHP22 EFFECTS OF DECENTRALIZED RESPONSIBILITY FOR COSTS OF OUTPATIENT PRESCRIPTION DRUGS ON THE PHARMACEUTICAL COST DEVELOPMENT IN SWEDEN

    Nov 1, 2005, 00:00

  • PRS7 COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND

    Nov 1, 2005, 00:00

  • PNL2 COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT TO PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL IN THE UK

    Nov 1, 2005, 00:00

  • PCV49 BELGIAN EVALUATION OF SCREENING AND TREATMENT OF HIGH RISK PATIENTS BASED ON WAIST AND AGE (BEST)

    Nov 1, 2005, 00:00

  • PUK36 PATIENT SATISFACTION- PSYCHOMETRIC VALIDATION OF THE OAB-S, AN OVERACTIVE BLADDER TREATMENT SATISFACTION QUESTIONNAIRE.

    Nov 1, 2005, 00:00

  • PCN23 ECONOMIC ASPECTS AND DRIVERS OF FEBRILE NEUTROPENIA IN CANCER—A MULTICENTRE RETROSPECTIVE ANALYSIS IN BELGIUM

    Nov 1, 2005, 00:00

  • PDB51 EVALUATING INTERVENTIONS ALONG THE COURSE OF DISEASE- MODELING DIABETES AND ITS MACROVASCULAR COMPLICATIONS

    Nov 1, 2005, 00:00

  • PMH8 THE HEATLH-RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY

    Nov 1, 2005, 00:00

  • PSN24 ATOPIC DERMATITIS- A CONJOINT ANALYSIS PILOT STUDY

    Nov 1, 2005, 00:00

  • PDB55 MEASURING QUALITY OF LIFE WITH EQ-5D IN AN AUSTRIAN OUTPATIENT CLINIC FOR PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2005, 00:00

  • PMC23 ECONOMIC EVALUATION OF MEDICAL DEVICES IN FRANCE- A CHALLENGE FOR HEALTH ECONOMISTS

    Nov 1, 2005, 00:00

  • CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID ...

    Nov 1, 2005, 00:00

  • PGI1 CLINICAL OUTCOMES OF RABEPRAZOLE IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE IN REAL-WORLD CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PHP17 EFFECTS OF GENERIC SUBSTITUTION ON THE DEVELOPMENT OF PHARMACEUTICAL EXPENDITURES DURING THE PERIOD JANUARY I 998 TO MAY 2005

    Nov 1, 2005, 00:00

  • PCN20 ORAL AND INTRAVENOUS CHEMOTHERAPY FOR FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK NHS SYSTEM

    Nov 1, 2005, 00:00

  • PHM2 THE COST OF CARE OF HEMOPHILIC PATIENTS WITHOUT INHIBITORS- THE COCHE STUDY

    Nov 1, 2005, 00:00

  • PMC13 ECONOMIC IMPACT OF HOSPITAL MALNUTRITION

    Nov 1, 2005, 00:00

  • PDB4 HEALTH CARE UTILIZATION AND EXPENDITURES ASSOCIATED WITH USE OF INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PEY12 PHARMACOECONOMIC ANALYSIS OF LATANOPROST VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA IN SPAIN

    Nov 1, 2005, 00:00

  • PPN7 COST-EFFECTIVENESS ANALYSIS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS CODEINE PLUS PARACETAMOL FOR POSTOPERATIVE PAIN THERAPY IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • POS4 COST-EFFECTIVENESS OF PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALENDRONATE ORALFACALCIDOL.THE STOP-STUDY- A RANDOMIZED PLACEBO-CONTROLLED TRIAL

    Nov 1, 2005, 00:00

  • PIN16 MEDICAL COSTS ASSOCIATED WITH NON-ADHERENCE TO ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS

    Nov 1, 2005, 00:00

  • PMH14 DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER

    Nov 1, 2005, 00:00

  • PCV13 EPIDEMIOLOGY AND COSTS OF ATRIAL TACHYARRHYTMIAS

    Nov 1, 2005, 00:00

  • PDB40 COST-UTILITY ANALYSIS IN A USA SETTING OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PUK3 CLINICAL IMPACT OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION

    Nov 1, 2005, 00:00

  • PCN53 MONITORING AND SECURING QUALITY IN ONCOLOGICAL CARE—THE 2004 LONGITUDINAL PASQOC® RESULTS

    Nov 1, 2005, 00:00

  • PIN25 PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS VACCINE (STAPHVAX) IN HEMODIALYSIS PATIENTS IN GERMANY

    Nov 1, 2005, 00:00

  • PGI13 THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY- A SYSTEMATIC REVIEW

    Nov 1, 2005, 00:00

  • PIH12 QUALITY OF LIFE AND HEALTH BEHAVIORS OF VENEZUELAN PHARMACY STUDENTS

    Nov 1, 2005, 00:00

  • PMH34 LONG-TERM TREATMENT OF SCHIZOPHRENIA FOR RELAPSE PREVENTION (LASER)- 6-MONTH OUTCOMES IN PATIENTS STARTED ON RISPERIDONE LONG-ACTING INJECTABLE IN GERMANY—DATA FROM THE E-STAR DATABASE

    Nov 1, 2005, 00:00

  • MC4 UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL

    Nov 1, 2005, 00:00

  • MC6 PERFORMANCE OF THE DMM SIMULATION MODEL IN PREDICTING REAL WORLD CHANGES IN GLYCEMIC CONTROL FOLLOWING DIAGNOSIS OF DIABETES

    Nov 1, 2005, 00:00

  • A Comparison of Self-Selectivity Corrections in Economic Evaluations and Outcomes Research

    Nov 1, 2005, 00:00

  • PCV67 FACTORS DETERMINING COMPLIANCE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN DAILY CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PCV80 COST ESTIMATION IN PATIENTS WITH AN ATHEROTROMBOTIC EVENT

    Nov 1, 2005, 00:00

  • PCN45 MULTILINGUAL VALIDATION OF THE FACT-LEUKEMIA IN 7 LANGUAGES

    Nov 1, 2005, 00:00

  • PDB31 A LIFETIME MODELLED ECONOMIC EVALUATION COMPARING PIOGLITAZONE AND ROSIGLITAZONE FORTHE TREATMENT OF TYPE-2 DIABETES MELLITUS IN THE UK

    Nov 1, 2005, 00:00

  • PPN2 THE COST-EFFECTIVENESS OF STRONG, CONTROLLED-RELEASE OPIOIDS FOR THE TREATMENT OF CHRONIC NON-MALIGNANT PAIN- A PROBABILISTIC DECISION-MODEL

    Nov 1, 2005, 00:00

  • PCV59 PHARMACO-ECONOMIC ANALYSIS OF VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ)VERSUS CANDESARTAN/HCTZ AND VERSUS TELMISARTAN/HCTZ IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN MEXICO

    Nov 1, 2005, 00:00

  • PAS9 THE SPANISH VERSION OF THE MINI-ASTHMA QUALITY OF LIFE QUESTIONNAIRE- EXAMINATION OF RESPONSIVENESS TO CHANGE

    Nov 1, 2005, 00:00

  • PMC25 ANALYSIS OF QUALITY OF LIFE DATA FROM DIFFERENT UTILITY INSTRUMENTS—AN EXAMPLE USING IMPUTATION

    Nov 1, 2005, 00:00

  • PUK35 VALIDATION OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI) IN A BRITISH POPULATION

    Nov 1, 2005, 00:00

  • PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING

    Nov 1, 2005, 00:00

  • DN3 COST-EFFECTIVENESS OF NON-INVASIVE IMAGING IN THE DIAGNOSIS OF PARKINSONISM

    Nov 1, 2005, 00:00

  • MC8 THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2005, 00:00

  • PDB58 DIABETIC PERIPHERAL NEUROPATHY- EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA) AND HEALTH-RELATED UTILITY (EQ5D)

    Nov 1, 2005, 00:00

  • PCV66 PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE) EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND POPULATION

    Nov 1, 2005, 00:00

  • PSN19 QUALITY OF LIFE OF PAEDIATRIC PATIENTS WITH ATOPIC ECZEMAANDTHEIR FAMILIES

    Nov 1, 2005, 00:00

  • PRS5 PHARMACOECONOMIC EVALUATION OFTIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

    Nov 1, 2005, 00:00

  • PR3 BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE

    Nov 1, 2005, 00:00

  • PIN18 DETERMINANTS OF HEALTH CARE COSTS IN AMBULATORY PATIENTS LIVING WITH HIV/AIDS

    Nov 1, 2005, 00:00

  • PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS- RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS

    Nov 1, 2005, 00:00

  • PCV42 RECENT TREND IN MANAGEMENT OF HYPERCHOLESTEROLEMIA AND GOAL ATTAINMENT

    Nov 1, 2005, 00:00

  • PMH27 12-MONTH COST-EFFECTIVENESS ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY

    Nov 1, 2005, 00:00

  • PCV62 LIPID PROFILE IN HYPERTENSIVES WITH AND WITHOUT CARDIOVASCULAR DISEASE- HAS THE HDL COLESTEROL BEEN FORGOTTEN?

    Nov 1, 2005, 00:00

  • PNL20 DISEASE SEVERITY AND HEALTH CARE COSTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

    Nov 1, 2005, 00:00

  • PMC14 POPULATION KNOWLEDGE- AN APPROACH TO CLASSIFY A GENERAL POPULATION ACCORDING TO LIFESTYLE, HEALTH BEHAVIOUR AND ATTITUDE

    Nov 1, 2005, 00:00

  • PCN2 LEAD TIME IN THE EVALUATION OF HISTORICAL SURVIVAL IMPROVEMENTS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • DN2 COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • UH2 COST DRIVERS IN MULTIPLE MYELOMA TREATMENT—A 2 YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED CHART REVIEW

    Nov 1, 2005, 00:00

  • PCN42 MODELLING THE EFFECT OF A NOVEL THERAPEUTIC AGENT ON THE EVOLUTION OF UTILITY IN REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2005, 00:00

  • POS5 THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS- A POLISH ANALYSIS

    Nov 1, 2005, 00:00

  • PMH17 HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS

    Nov 1, 2005, 00:00

  • PSN12 NAIL PSORIASIS- ELABORATION OF A SCALE FOR FUNCTIONAL DISCOMFORT

    Nov 1, 2005, 00:00

  • PCV12 MANAGEMENT PATTERNS AND COSTS OF ATRIAL FIBRILLATION IN A LARGE COMMERCIALLY INSURED U.S. POPULATION

    Nov 1, 2005, 00:00

  • PCV52 IMPACT OF COMPLIANCE AND PERSISTENCE OF TREATMENT WITH VALSARTAN ON HYPERTENSION CLINICAL OUTCOMES

    Nov 1, 2005, 00:00

  • Supplement- Empirical Explorations in the Green and Growing Field of Treatment Satisfaction

    Nov 1, 2005, 00:00

  • QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN

    Nov 1, 2005, 00:00

  • IN3 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMALAMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK

    Nov 1, 2005, 00:00

  • PHP8 RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY

    Nov 1, 2005, 00:00

  • PIN24 ADDING A QUADRIVALENT (6, I I, 16 18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING UK CERVICAL SCREENING PROGRAMME IS POTENTIALLY COST-EFFECTIVE

    Nov 1, 2005, 00:00

  • PPN5 A MODEL-BASED COST-UTILITY ANALYSIS OF LYRICA™(PREGABALIN) VERSUS CURRENT PHARMACEUTICAL MANAGEMENT OF PERIPHERAL NEUROPATHIC PAIN

    Nov 1, 2005, 00:00

  • PUK19 EXPLORING NEUROGENIC DETRUSOR OVERACTIVITY WITHIN AN OVERACTIVE BLADDER POPULATION

    Nov 1, 2005, 00:00

  • PGI9 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN SWEDEN

    Nov 1, 2005, 00:00

  • PMH4 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS- MENTAL HEALTH AND PHYSICAL CO-MORBIDITY IN NORDBADEN/GERMANY

    Nov 1, 2005, 00:00

  • IN4 LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION- AN ECONOMIC EVALUATION FOR FOUR EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PSU3 THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING COLORECTAL SURGERY

    Nov 1, 2005, 00:00

  • PDB62 TREATMENT SATISFACTION IN SUBJECTS WITH TYPE-2 DIABETES RECEIVING INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PMC11 DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A U.S. MEDICAID POPULATION

    Nov 1, 2005, 00:00

  • PRS11 MANAGEMENT OF COPD IN BELGIUM- A REAL LIFE COST OF ILLNESS STUDY

    Nov 1, 2005, 00:00

  • PCV73 USE OF PROPENSITY SCORE METHODOLOGY IN CARDIOVASCULAR DEVICE TRIALS- U.S. FOOD AND DRUG ADMINISTRATION PERSPECTIVES

    Nov 1, 2005, 00:00

  • PGI23 ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITYWHILE ATWORKAND IN DAILY ACTIVITIES—RESULTS FROMA RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY

    Nov 1, 2005, 00:00

  • PUK34 EVALUATION OF TWO TENSION FREE VAGINAL TAPES WITH URODYNAMICS AND ICIQ-UI SF QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PHP30 PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF PSYCHOTROPIC DRUGS IN A MAJOR HEALTH CARE SYSTEM IN SAUDI ARABIA

    Nov 1, 2005, 00:00

  • PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER

    Nov 1, 2005, 00:00

  • PCN40 DEVELOPMENT OF AN ALGORITHM FOR THE IDENTIFICATION AND CLASSIFICATION OF COLORECTAL CANCER (CRC) PATIENTS ACCORDING TO FIRST-LINE CHEMOTHERAPY +/− BEVACIZUMAB, AND INITIATION OF SECOND-LINE THERAPY USING ADMINISTRATIVE CLAIMS RECORDS

    Nov 1, 2005, 00:00

  • PRS20 PATIENT REPORTED IMPACT OF COUGH AND SPUTUM IN CHRONIC (OBSTRUCTIVE) BRONCHITIS—SIMULTANEOUS DEVELOPMENT OF THE SELF-ADMINISTERED CASA-Q

    Nov 1, 2005, 00:00

  • PMC17 RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE

    Nov 1, 2005, 00:00

  • PCV63 CARDIOVASCULAR DRUG USE IN NIS REGION

    Nov 1, 2005, 00:00

  • PDB36 COST OF TYPE-2 DIABETES MELLITUS IN HONG KONG CHINESE

    Nov 1, 2005, 00:00

  • PHP43 IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS

    Nov 1, 2005, 00:00

  • PEY1 ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)

    Nov 1, 2005, 00:00

  • PMC18 PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN COMPUTER-BASED VERSION OF THE SF-36

    Nov 1, 2005, 00:00

  • QL3 “FAMIDIAL STUDY”- ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON DIALYSIS PATIENTS' HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN

    Nov 1, 2005, 00:00

  • PAS7 THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA- RESULTS FROM A MULTINATIONAL STUDY

    Nov 1, 2005, 00:00

  • PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE

    Nov 1, 2005, 00:00

  • PUK28 LONG-TERM DARIFENACIN TREATMENT FOR OVERACTIVE BLADDER- QUALITY OF LIFE OUTCOMES FROM A 2-YEAR, OPEN-LABEL EXTENSION STUDY

    Nov 1, 2005, 00:00

  • PCN9 COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • PDB29 HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS- THE COCHE STUDY

    Nov 1, 2005, 00:00

  • PMD3 A COST EFFECTIVENESS MODEL FOR THE EVALUATION OF TOTAL HIP ARTHROPLASTY (THA) AND TOTAL KNEE ARTHROPLASTY (TKA) IN SWEDEN

    Nov 1, 2005, 00:00

  • PCV45 THE ECONOMIC ASSESSMENT OF SWITCHING TO DUAL INHIBITION CHOLESTEROL LOWERING THEARPY IN FINLAND

    Nov 1, 2005, 00:00

  • PIN26 COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER RESPIRATORYTRACT INFECTIONS WITH NONSPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT

    Nov 1, 2005, 00:00

  • PST9 MANDARIN VERSION OF STROKE IMPACT SCALE- ADAPTATION AND VALIDATION

    Nov 1, 2005, 00:00

  • PHP48 A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS IN PHARMACEUTICAL ADVERTISING

    Nov 1, 2005, 00:00

  • PGI17 ARTIFICIAL LIVER SUPPORT SYSTEMS—A MEDICAL AND HEALTH ECONOMIC HTA-REPORT

    Nov 1, 2005, 00:00

  • PMH38 A DISCRETE EVENT SIMULATION (DES) MODEL TO DESCRIBE SCHIZOPHRENIA

    Nov 1, 2005, 00:00

  • PUK14 COST OF ILLNESS OF FEMALE LOWER URINARYTRACT SYMPTOMS (LUTS)

    Nov 1, 2005, 00:00

  • PFM1 FIBROMYALGIA SYNDROME- A PORTUGUESE EPIDEMIOLOGICAL SURVEY

    Nov 1, 2005, 00:00

  • PMC9 THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES

    Nov 1, 2005, 00:00

  • PED2 LONG-TERM QUALITY OF LIFE (QOL) OUTCOMES IN THE TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD)—A 5 YEAR STUDY

    Nov 1, 2005, 00:00

  • PSN9 PATTERNS OF TOPICAL ACNE PRESCRIPTION MEDICATION USE- ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE

    Nov 1, 2005, 00:00

  • PHP31 CHARGES FOR HOSPITAL ADMISSIONS ATTRIBUTABLE TO HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN SOUTH CAROLINA DURING 1998-2002

    Nov 1, 2005, 00:00

  • PAS8 ASTHMA RELATED QUALITY OF LIFE IS CORRELATED WITH ASTHMA CONTROL AMONG RESPIRE STUDY PARTICIPANTS

    Nov 1, 2005, 00:00

  • PUK9 COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM- THE EXPERIENCE IN ITALY

    Nov 1, 2005, 00:00

  • PHP39 PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES

    Nov 1, 2005, 00:00

  • PSN17 VALIDATION OF THE ITALIAN VERSION OF THE INFANTS' DERMATITIS QUALITY OF LIFE FAMILY DERMATITIS INDEXES

    Nov 1, 2005, 00:00

  • PHP27 PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)

    Nov 1, 2005, 00:00

  • PMC10 A METHODOLOGICAL APPROACH TO ASSESS COST DATA IN THE CONTEXT OF A DECISION ANALYTIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF THE METABOLIC SYNDROME

    Nov 1, 2005, 00:00

  • PCV84 SURGICAL TREATMENT OF ABDOMINAL AORTIC ANEURISM- ANALYSIS OF OPERATING COSTS. ENDOVASCULAR TREATMENT VERSUS TRADITIONAL SURGERY

    Nov 1, 2005, 00:00

  • PNL7 IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS EFFICIENT FROM A SOCIETAL PERSPECTIVE?

    Nov 1, 2005, 00:00

  • PMH44 DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD- A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

    Nov 1, 2005, 00:00

  • PIH7 QUALITY OF LIFE OF ITALIAN GENERAL POPULATION AGED 40 TO 79 YEARS OLD

    Nov 1, 2005, 00:00

  • PDB18 COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA- A UK PERSPECTIVE

    Nov 1, 2005, 00:00

  • PEY15 COST OF ENDOPHTHALMITIS- A NATIONWIDE APPROACH

    Nov 1, 2005, 00:00

  • POS2 CLINICAL EFFICACY AND SAFETY OF BALLOON KYPHOPLASTY FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2005, 00:00

  • PDB43 SHOULD WE LOOK FOR A NEWAPPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?

    Nov 1, 2005, 00:00

  • CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • PGI11 IBD- INDIRECT COSTS OF ILLNESS AND QUALITY OF LIFE IN GERMANY

    Nov 1, 2005, 00:00

  • Assessing Patient Satisfaction- Concepts, Applications, and Measurement

    Nov 1, 2005, 00:00

  • CV3 A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE

    Nov 1, 2005, 00:00

  • POB2 PREVALENCE TRENDS IN OVERWEIGHT AND OBESITY AND WEIGHT CONTROL PRACTICES AMONG ADULTS IN THE US

    Nov 1, 2005, 00:00

  • PUK31 DEVELOPMENT AND PILOT TESTING OF A NEW SCALE SPECIFICALLY MEASURING THE IMPACT OF STRESS URINARY INCONTINENCE (SUI) ON COMMON PHYSICAL ACTIVITIES OF DAILY LIFE

    Nov 1, 2005, 00:00

  • PCV44 COST-EFFECTIVENESS OF ROSUVASTATIN IN THE PREVENTION OF ISCHEMIC HEART DISEASE IN PORTUGAL

    Nov 1, 2005, 00:00

  • PMH12 THE NORDBADEN PROJECT FOR HEALTH CARE UTILIZATION RESEARCH IN GERMANY

    Nov 1, 2005, 00:00

  • PCN50 A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • POB9 EVALUATION OF THE ASSOCIATION BETWEEN BODY MASS INDEX, WAIST CIRCUMFERENCE AND HEALTH-RELATED UTILITY (EQ5D)

    Nov 1, 2005, 00:00

  • PMD2 COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM

    Nov 1, 2005, 00:00

  • PMC16 THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY

    Nov 1, 2005, 00:00

  • PGI18 META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES

    Nov 1, 2005, 00:00

  • PGI2 COST EFFECTIVENESS AND BUDGET IMPACT OF LAMIVUDINE ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS TYPE B PATIENTS IN TAIWAN

    Nov 1, 2005, 00:00

  • PIN14 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION- ESTIMATES FROM INFECTED AMERICANS

    Nov 1, 2005, 00:00

  • Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective

    Nov 1, 2005, 00:00

  • QL4 VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • PHP2 IMPLEMENTATION OF AN EVIDENCE BASED GUIDELINE FOR CLINICAL NUTRITION IN A 500 BED HOSPITAL IN NORTHERN GERMANY- INFLUENCE ON DIRECT COST FOR CLINICAL NUTRITION

    Nov 1, 2005, 00:00

  • PMH48 QUALITY OF LIFE IN MAJOR DEPRESSION- RESULTS OF THE MC3 TRIAL

    Nov 1, 2005, 00:00

  • PGI19 GASTROESOPHAGEAL REFLUX DISEASE (GERD) COST OF CARE- ROLE OF NAÏVE AND RELAPSED SYMPTOMS IN GENERAL PRACTICE

    Nov 1, 2005, 00:00

  • PHP34 EFFECTS OF MEDICAL SAVINGS ACCOUNTS ON HEALTH CARE UTILIZATION AND HEALTH EXPENDITURE- EVIDENCE FROM CHINA

    Nov 1, 2005, 00:00

  • PSN13 REFINEMENT AND REDUCTION OF THE IMPACT OF PSORIASIS QUESTIONNAIRE- CLASSICAL TEST THEORY VS RASCH ANALYSIS

    Nov 1, 2005, 00:00

  • PCN17 THE COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN FORTHE TREATMENT OF PATIENTS WITH EGFR-EXPRESSING METASTATIC COLORECTAL CANCER AFTER FAILURE OF IRINOTECAN-INCLUDING CYTOTOXIC THERAPY IN SCOTLAND

    Nov 1, 2005, 00:00

  • PIN21 SELF ASSESSED HEALTH-RELATED QUALITY OF LIFE AMONG HIV PATIENT IN UK

    Nov 1, 2005, 00:00

  • PNL8 COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR VERTIGO

    Nov 1, 2005, 00:00

  • PUK1 THE TIMELY CONSTRUCTION OF AN ARTERIOVENOUS FISTULAE- A KEY FACTOR IN REDUCING MORBIDITY AND MORTALITY AND IMPROVING ECONOMIC EFFECTIVENESS

    Nov 1, 2005, 00:00

  • PMH20 RELATION BETWEEN SYMPTOMS IN SCHIZOPHRENIA AND RISK OF HARM TO SELF AND OTHERS

    Nov 1, 2005, 00:00

  • PEY2 USE OF NEURAL NETWORKS TO PREDICT NIGHT INTRA-OCULAR PRESSURE (IOP) PEAK CONTROL BY PROSTAGLANDIN ANALOGUES

    Nov 1, 2005, 00:00

  • PCV28 IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING COSTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIS)

    Nov 1, 2005, 00:00

  • POS9 EXTENDING THE BURDEN OF DISEASE PROTOCOL- DERIVING DISABILITY WEIGHTS FOR RISK FACTOR DISEASES—THE CASE FOR OSTEOPOROSIS

    Nov 1, 2005, 00:00

  • PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PPN10 PSYCHOMETRIC PROPERTIES OF THE MOS-SLEEP SCALE IN NEUROPATHIC PAIN (NEP) SYNDROMES

    Nov 1, 2005, 00:00

  • PUK11 COST ANALYSIS OF RENAL REPLACEMENT THERAPIES IN LATVIA

    Nov 1, 2005, 00:00

  • PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY

    Nov 1, 2005, 00:00

  • PHP5 COST OF SEVERE BLUNT TRAUMA IN THE UK

    Nov 1, 2005, 00:00

  • PNL9 COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION POLICIES IN SOUTH AFRICA

    Nov 1, 2005, 00:00

  • PCV86 THE ECONOMIC BURDEN OF EXPERIENCING MAJOR COMPLICATIONS DURING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2005, 00:00

  • PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY

    Nov 1, 2005, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166 (current)
  • 167
  • 168
  • 169
  • 170
  • »